Abstract: A gas mixer (10) for mixing a first gas stream with a second gas stream includes an impact labyrinth (24) in the first gas stream having structures (25), e.g., corrugated walls, forming a tortuous path through which the first gas stream must pass en route to a mixing point (20) in the gas mixer. The labyrinth fosters ignition of particles entrained in the first gas stream. Elongate, straight pipes (30) receive the first gas stream from the impact labyrinth (24) and carrying the first gas stream to the mixing point (20) the pipes (30) are positioned with a vessel (12) carrying the second gas stream. The pipes (30) have openings which are substantially aligned with the flow direction of the second gas stream at the mixing point (20) thereby introducing the first gas stream into the second gas stream in a low shear manner.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4, X and Y are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3 and X are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4 and X are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The invention relates to oxazolopyrimidine compounds of formula I, where A, R1 and R2 are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonists The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: The present invention relates to cycloalkyloxycarboxylic acid derivatives of the formula I in which A, R1, R2a, R2b, R2c, R3 and X are as defined in the claims. The compounds of the formula I are suitable, for example, for wound healing.

Abstract: The invention therefore relates to compounds of the formula I in which X, Y, R1, R2 and R3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

Abstract: The invention therefore relates to compounds of the formula I in which A, X, Y, R1, R2 and R3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

Abstract: Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring The invention therefore relates to compounds of the formula I in which X, Y, R1, R2 and R3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

Abstract: A chiplessly thread-forming screw has a stem (11) at one end of which a tip (13) is provided and at another end of which a head (14) is provided, and which has a pointed conical section (21) extending from the tip (13) in a direction of the head (14), a cylindrical section (25) arranged between the first pointed section (21) and the head (14), a first cambered section (22) adjoining the pointed conical section (21) in the direction of the head, and a second cambered section (24) arranged between the first cambered section (22) and the cylindrical section (25) and an outer surface (16) of which has a second curvature radius (R2) unequal to the first curvature radius (R1) of the outer surface (12) of the first cambered section (21).

Abstract: The invention provides a mixing system comprising the following: A) at least one extensional flow mixer comprising: a generally open and hollow body having a contoured outer surface and having: a single entrance port and a single exit port; a means for compressing a bulk stream flowing through the generally open and hollow body in a direction of flow, and at least one injected additive stream introduced at the single entrance port in the direction of flow; and a means for broadening the bulk stream and the at least one injected additive stream, such that an interfacial area between the bulk stream and the at least one injected additive stream is increased as the bulk stream and the at least one injected additive stream flow through the generally open and hollow body in the direction of flow to promote mixing of the bulk stream and the at least one injected additive stream; B) a flow conductor having an axis and having a generally open and hollow flow mixer body cured therein; and C) a primary additive stream

Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-?) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: Insulated glass units are sealed with polyurethane made using a natural oil-based polyol (NOBP). In one embodiment the NOBP is made using a monol-rich monomer containing high levels of mono-hydroxy functional fatty acid methyl esters. Insulated glass sealants based on these compounds provide enhanced resistance to UV and oxidative degradation as compared to conventional products while still providing the required barrier and mechanical properties.

Abstract: Natural oil-based polyols that are high in color, e.g., >40 APHA, are decolorized when exposed to high frequency visible light and/or low frequency UV light, with or without the combination of heat and/or air exposure.

Abstract: The invention relates to a medical device for infusion of an active ingredient or removal of a body tissue or body liquid comprising: a outlet device for infusion of an active ingredient to a body tissue; a receptacle for storing the active ingredient to which the outlet device is attachable; a sensor device for measuring a parameter which is related to a physical state in the body tissue; a drive device for effectuating at least an infusion of the active ingredient; characterized by a control unit functionally connected to the sensor device for receiving a sensor signal, which corresponds to the state of the body tissue, wherein the control unit is adapted for controlling a flow rate.